2019
Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer
Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Seo S, Kang H, Kim W, Lee J, Ryu D, Choi J, Kim I, Moon S, Choi Y, Yun S, Kim W. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer 2019, 17: e704-e711. PMID: 31088707, DOI: 10.1016/j.clgc.2019.04.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorBone Morphogenetic Protein 4Cell-Free Nucleic AcidsDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorGTPase-Activating ProteinsHumansMaleMiddle AgedNuclear ProteinsPrognosisSurvival AnalysisUrinary Bladder NeoplasmsConceptsProgression-free survivalCox regression analysisRecurrence-free survivalDisease recurrenceBladder cancerNon-muscle invasive bladder cancerInvasive bladder cancer patientsWorse progression-free survivalMultivariate Cox regression analysisWorse recurrence-free survivalKaplan-Meier analysisKaplan-Meier curvesBladder cancer patientsRegression analysisUrinary cell-free DNAValuable novel biomarkersCell-free DNANMIBC patientsClinical outcomesCancer patientsDisease progressionPrognostic markerReal-time PCRNovel biomarkersIndependent factors
2018
Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria
Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Kang H, Kim W, Lee J, Kim I, Moon S, Choi Y, Yun S, Kim W. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology Seminars And Original Investigations 2018, 37: 86-96. PMID: 30446454, DOI: 10.1016/j.urolonc.2018.10.023.Peer-Reviewed Original ResearchConceptsBladder cancerUrinary cell-free DNACell-free DNAScreening groupHematuria patientsValidation cohortPredictive valueUrine-based markersNegative predictive valuePositive predictive valueGood diagnostic performanceStudy cohortBC patientsUrological cancersNoninvasive biomarkersPatientsScore indexDiagnostic valueHematuriaExpression level ratioLiquid biopsyCohortDiagnostic performanceCancerDS-index
2017
Garlic extract in bladder cancer prevention: Evidence from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis
Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Seo Y, Choe S, Kim D, Kim S, Moon S, Choi Y, Lee G, Kim I, Yun S, Kim W. Garlic extract in bladder cancer prevention: Evidence from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis. International Journal Of Oncology 2017, 51: 204-212. PMID: 28498422, DOI: 10.3892/ijo.2017.3993.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisBiomarkers, TumorCell ProliferationGarlicGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMaleMiceMice, Inbred BALB CMice, NudePlant ExtractsSignal TransductionTissue Array AnalysisTumor Cells, CulturedUrinary Bladder NeoplasmsXenograft Model Antitumor AssaysConceptsCancer preventionBladder cancerGarlic extractXenograft modelNude mouse xenograft modelAcceptable safety profileBladder cancer preventionCancer prevention activitiesCell xenograft modelBALB/cTissue microarray analysisMouse xenograft modelMicroarray analysisTumor weightBC patientsSafety profileTumor volumeTissue microarrayControl groupGene network analysisControl dietPrevention activitiesPreventionExtract intakePotential mechanisms
2015
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer
Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.Peer-Reviewed Original ResearchConceptsFavorable-risk prostate cancerRisk prostate cancerProstate-specific antigenProstate cancerSpecific antigenActive surveillancePathological outcomesAntigen groupRadical prostatectomyBiochemical recurrence-free survival rateElevated prostate-specific antigenProstate specific antigen cutoffLow-risk prostate cancerProstate-specific antigen levelRecurrence-free survival ratesFavorable risk diseaseMulti-institution databaseSpecific antigen levelsAdverse pathological outcomesTreatment of choiceDatabase of menHigh groupOncologic outcomesRisk diseaseAntigen levelsLower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics
Kim E, Kim Y, Kang H, Yoon H, Kim W, Kim Y, Yun S, Moon S, Choi Y, Kim I, Lee S, Kim W. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal Of Korean Medical Science 2015, 30: 937-942. PMID: 26130958, PMCID: PMC4479949, DOI: 10.3346/jkms.2015.30.7.937.Peer-Reviewed Original ResearchConceptsProstate cancerClinicopathological characteristicsElevated prostate-specific antigen levelsProstate-specific antigen levelBenign prostatic hyperplasia patientsNon-metastatic diseaseAggressive clinicopathologic featuresLow PSA levelsSpecific antigen levelsProstatic hyperplasia patientsAggressive clinicopathological characteristicsLow Gleason scoreHuman prostate cancerCharacteristic curve analysisProstate cancer susceptibilityPSA levelsMetastatic diseasePCa patientsClinicopathologic featuresHyperplasia patientsAntigen levelsGleason scoreClinicopathological parametersPCa tissuesReal-time PCRIncreased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma
Ha Y, Lee G, Modi P, Kwon Y, Ahn H, Kim W, Kim I. Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma. Journal Of Urology 2015, 194: 1441-1448. PMID: 25796113, DOI: 10.1016/j.juro.2015.03.078.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBlotting, WesternCarcinoma, Renal CellCell Line, TumorDisease ProgressionFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisReal-Time Polymerase Chain ReactionReceptors, AndrogenRetrospective StudiesRNA, NeoplasmTime FactorsYoung AdultConceptsRenal cell carcinomaAndrogen receptor mRNA expressionReceptor mRNA expression levelsCancer-specific survivalCell carcinomaCell carcinoma cell linesReceptor mRNA expressionHuman renal cell carcinoma cell linesRenal cell carcinoma cell linesAndrogen receptorMRNA expression levelsSpecific survivalCarcinoma cell linesMultivariate Cox regression analysisLocalized Renal Cell CarcinomaMRNA expressionT2 renal cell carcinomaCell linesPathological stage T1Androgen receptor expressionCox regression analysisKaplan-Meier estimatesReceptor-positive cell linesChain reactionPositive renal cell carcinomasPathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center.
Ha Y, Yu J, Patel N, Hassanzadeh Salmasi A, Parihar J, Kwon T, Kim W, Kim I. Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center. Minerva Urologica E Nefrologica 2015, 67: 1-9. PMID: 25664959.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyRadical prostatectomyActive surveillanceAdvanced diseaseUnderwent robot-assisted radical prostatectomyLow-risk prostate cancerLower prostate volumePSA density levelsLow-risk diseaseActive surveillance cohortOrgan-confined diseaseSpecimens of patientsAdvanced pathologic featuresProspective cohortAdditional patientsPathologic featuresPathologic findingsProstate volumeSingle centerProspective studyGleason scoreSurveillance cohortDefinitive interventionClinicopathological resultsPathologic analysis
2014
Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH
Yun S, Yan C, Jeong P, Kang H, Kim Y, Kim E, Lee O, Kim W, Moon S, Kim I, Choi Y, Kim W. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH. Annals Of Surgical Oncology 2014, 22: 2439-2445. PMID: 25348783, DOI: 10.1245/s10434-014-4194-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorCalgranulin ACalgranulin BCase-Control StudiesFollow-Up StudiesHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingNucleic AcidsPrognosisProstatic HyperplasiaProstatic NeoplasmsReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateConceptsS100A8/A9CAP patientsAcid levelsNucleic acid levelBPH tissueProstate cancerS100A8/A9 expressionBenign prostatic hyperplasia tissuesRecurrence-free timeProstatic hyperplasia tissuesUrinary nucleic acidsBPH patientsIndependent predictorsTransurethral resectionAggressive diseaseChronic inflammationPoor prognosisPrognostic valueTransurethral prostatectomyProstatectomy patientsBiochemical recurrencePrognostic markerS100A9 expressionA9 expressionImmunohistochemical stainingDecreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma
Ha Y, Lee G, Kim Y, Kwon S, Choi S, Kim T, Kwon T, Yun S, Kim I, Kim W. Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma. World Journal Of Surgical Oncology 2014, 12: 288. PMID: 25227434, PMCID: PMC4176564, DOI: 10.1186/1477-7819-12-288.Peer-Reviewed Original ResearchAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, PapillaryCarcinoma, Renal CellCase-Control StudiesFemaleFollow-Up StudiesHumansKidney NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSelenium-Binding ProteinsSurvival RateYoung AdultDiagnosis of bladder cancer and prediction of survival by urinary metabolomics
Jin X, Yun S, Jeong P, Kim I, Kim W, Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget 2014, 5: 1635-1645. PMID: 24721970, PMCID: PMC4039236, DOI: 10.18632/oncotarget.1744.Peer-Reviewed Original ResearchConceptsBladder cancerControl groupCancer groupCancer-specific survival timeMuscle-invasive bladder cancerInvasive bladder cancerMetabolomic profilesPrediction of survivalHigh-performance liquid chromatography-quadrupole timeLiquid chromatography-quadrupole timeUrinary metabolomicsCommon cancerControl subjectsUrinary cytologyBC diagnosisDiagnostic modalitiesSurvival timeCurrent modalitiesUrine metabolitesMetabolomics-based approachPatientsCancerDifferential metabolitesClinical applicabilityCarnitine transferase
2012
Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer
YUN S, JEONG P, KIM W, KIM T, LEE Y, SONG P, CHOI Y, KIM I, MOON S, KIM W. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. International Journal Of Oncology 2012, 41: 1871-1878. PMID: 22961325, DOI: 10.3892/ijo.2012.1622.Peer-Reviewed Original ResearchConceptsBladder cancerCell-free miRNAsMiR-200aMiR-145Transitional cell carcinomaBladder cancer patientsNon-cancer controlsHealthy normal controlsMiR-145 levelsMiR-200a levelsCell-free microRNAsNMIBC recurrenceIndependent predictorsClinicopathological featuresCell carcinomaCancer patientsPrognostic biomarkerUrinary bladderHigh riskNoninvasive biomarkersNormal controlsAccurate biomarkersMultivariate analysisPatientsCancerRas Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer
Kim J, Chae Y, Ha Y, Kim I, Byun S, Yun S, Kim W. Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2012, 10: 114-120. PMID: 22382007, DOI: 10.1016/j.clgc.2011.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Transitional CellChildDNA MethylationFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosisPromoter Regions, GeneticProportional Hazards ModelsTumor BurdenTumor Suppressor ProteinsUrinary Bladder NeoplasmsYoung AdultConceptsRecurrent nonmuscle invasive bladder cancerNonmuscle invasive bladder cancerMuscle-invasive bladder cancerInvasive bladder cancerPrimary BC tissuesCox regression analysisBladder cancerPrognostic markerRASSF1A methylationRASSF1A hypermethylationIndependent predictorsBC tissuesMultivariate Cox regression analysisCancer progressionKaplan-Meier analysisAdvanced tumor stagePromising prognostic markerPromoter hypermethylationPotential prognostic markerRegression analysisRASSF1A promoter hypermethylationMethylation-specific polymerase chain reactionClinicopathologic featuresPrognostic significanceKaplan-Meier
2011
Novel combination markers for predicting progression of nonmuscle invasive bladder cancer
Ha Y, Kim J, Yoon H, Jeong P, Kim T, Yun S, Lee S, Kim G, Choi Y, Moon S, Kim I, Kim W. Novel combination markers for predicting progression of nonmuscle invasive bladder cancer. International Journal Of Cancer 2011, 131: e501-e507. PMID: 22025348, DOI: 10.1002/ijc.27319.Peer-Reviewed Original ResearchConceptsNonmuscle invasive bladder cancerInvasive bladder cancerMethylation-specific polymerase chain reactionBladder cancerNMIBC progressionMultivariate Cox regression analysisPredictive combinationCox regression analysisKaplan-Meier estimatesMRNA expression levelsBest predictive combinationMedian followRUNX3 promoter methylationIntravesical therapyPrognostic effectSpecific polymerase chain reactionSubgroup analysisEffect of RUNX3Prognostic markerReal-time PCRHigh riskCombination markersPatientsMRNA expressionProgressionEFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling
Kim Y, Yoon H, Kim S, Kim Y, Kim E, Kim I, Kim W. EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling. Clinical Cancer Research 2011, 17: 4523-4530. PMID: 21571867, DOI: 10.1158/1078-0432.ccr-10-2817.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAzacitidineBiomarkers, TumorCell Line, TumorCpG IslandsDecitabineDNA MethylationDNA Modification MethylasesEpigenomicsExtracellular Matrix ProteinsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPromoter Regions, GeneticProstatic HyperplasiaProstatic NeoplasmsReproducibility of ResultsConceptsEpidermal growth factor-containing fibulin-like extracellular matrix protein 1DNA methylationGene Expression OmnibusExpression profilingProstate cell linesGenome-wide characterizationCell linesMethylation statusExtracellular matrix protein 1Methylation markersDNA methylation profilesBisulfite sequencing analysisFibulin-like extracellular matrix protein 1Aberrant methylation patternsAbnormal DNA methylationExpression levelsNovel methylation markersGene expression analysisGene expression profilingNovel DNA methylation markersMatrix protein 1Gene expression dataGene expression levelsMicroarray gene expression dataMethylation patternsGSTM1 Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer
Ha Y, Yan C, Jeong P, Kim W, Yun S, Kim I, Moon S, Kim W. GSTM1 Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer. Journal Of Korean Medical Science 2011, 26: 231-236. PMID: 21286014, PMCID: PMC3031007, DOI: 10.3346/jkms.2011.26.2.231.Peer-Reviewed Original ResearchConceptsNon-muscle invasive bladder cancerInvasive bladder cancerTumor recurrencePolymerase chain reactionTissue genotypeBladder cancerMultivariate Cox regression analysisGlutathione S-transferaseCox regression analysisGlutathione S-transferase muCox regression modelKaplan-Meier estimatesBladder tumor recurrencePrognosis of BCBladder cancer developmentBC tissue samplesGlutathione S-transferase thetaTissue genotypingIndependent predictorsPrognostic significanceKaplan-MeierBlood genomic DNAClinicopathological parametersRecurrence predictorsGSTM1 genotype
2010
HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Progression
Yim M, Ha Y, Kim I, Yun S, Choi Y, Kim W. HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Progression. Journal Of Urology 2010, 185: 701-705. PMID: 21168882, DOI: 10.1016/j.juro.2010.09.081.Peer-Reviewed Original ResearchAgedBiomarkers, TumorBiopsy, NeedleCarcinoma, Transitional CellCohort StudiesCystectomyDisease ProgressionFemaleGene Expression Regulation, NeoplasticHeme Oxygenase-1HumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm Recurrence, LocalPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSensitivity and SpecificitySurvival AnalysisUrinary Bladder NeoplasmsAnalysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping
Kim E, Yan C, Ha Y, Jeong P, Kim I, Moon S, Choi Y, Kim W. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urologic Oncology Seminars And Original Investigations 2010, 30: 673-679. PMID: 20884250, DOI: 10.1016/j.urolonc.2010.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorDNA GlycosylasesFemaleGene FrequencyGenotypeHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMusclesNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingPeptide Nucleic AcidsPolymerase Chain ReactionPolymorphism, GeneticPrognosisProportional Hazards ModelsUrinary Bladder NeoplasmsConceptsMuscle-invasive bladder cancerReal-time PCR clampingInvasive bladder cancerBladder cancerHOGG1 genotypeHOGG1 codon 326 genotypesMultivariate Cox regression analysisHOGG1 codon 326Cancer-specific survivalCox regression analysisPrognostic genetic markersPCR clampingSpecific survivalSurvival benefitClinicopathologic characteristicsBC patientsPrognostic indicatorTumor gradePrognostic markerClinical dataProtective effectCancerPatientsDNA damage repair mechanismsCodon 326
2001
Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma
Shariat S, Kim J, Andrews B, Kattan M, Wheeler T, Kim I, Lerner S, Slawin K. Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001, 92: 2985-2992. PMID: 11753975, DOI: 10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsMuscle-invasive transitional cell carcinomaTransitional cell carcinomaT1 transitional cell carcinomaPreoperative plasma levelsPlasma TGFDisease recurrenceIndependent predictorsLymph nodesClinical outcomesPlasma levelsBladder carcinomaGrowth factorDisease-specific mortalityDisease-specific survivalRegional lymph nodesSubgroup of patientsStrong independent predictorGrowth factor-β1Intravesical immunoCarcinoma metastaticLymphovascular invasionSpecific survivalRadical cystectomyPathologic featuresCell carcinomaPreoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
Shariat S, Shalev M, Menesses-Diaz A, Kim I, Kattan M, Wheeler T, Slawin K. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. Journal Of Clinical Oncology 2001, 19: 2856-64. PMID: 11387358, DOI: 10.1200/jco.2001.19.11.2856.Peer-Reviewed Original ResearchConceptsProstate cancer metastaticPlasma TGFPreoperative plasma levelsRegional lymph nodesRadical prostatectomyCancer metastaticPSA progressionLymph nodesGleason sumPlasma levelsGrowth factorLocal-only failureOccult metastatic diseasePathologic Gleason sumPostoperative multivariate analysisOrgan-confined diseaseSurgical margin statusLymph node metastasisBiopsy Gleason sumRadical prostatectomy patientsProstate cancer invasionMetastatic diseaseBone metastasesConsecutive patientsMargin status
1998
Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes.
Lee D, Yang S, Hong S, Chung B, Kim I. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clinical Cancer Research 1998, 4: 535-8. PMID: 9533519.Peer-Reviewed Original ResearchConceptsTransitional cell carcinomaBladder transitional cell carcinomaBladder washesCell carcinomaCytological diagnosisTelomerase activityGrade 1 transitional cell carcinomaCancer tissuesNormal tissuesHuman bladder cancer tissuesBladder wash samplesPositive telomerase activityFinal pathological diagnosisLow-grade tumorsBladder cancer tissuesTelomeric repeat amplificationPositive cytologyTransurethral resectionBladder tumorsBladder cancerPathological diagnosisWash samplesCytological specimensPatientsPotential marker